Financial support and resources available for businesses impacted by COVID-19.

Support for businesses impacted by COVID-19.

GeminX

Gemin X specialized in the discovery and development of novel therapeutics that modulate apoptosis, the body's natural ability to destroy diseased or damaged cells, in life-threatening diseases. The company is also applying its apoptotic platforms to develop additional products. Apoptosis is an important and normal biological process that plays a vital role in the physiological maintenance of a variety of tissues in the body.

Cephalon acquired Gemin X.

Investment year: 2001
Industry sector: Biotechnology
Region: Quebec
Website
Follow GeminX
BDC Venture Capital Partner

Ela Borenstein

Program Director